Newsfeeds - Spark Newswire

3 minute read

FDA
News

Puma Biotech Highlights Presentation Of Data From Phase 3 ExteNET Trial In Early Stage HER2-Positive Breast Cancer Patients At American Society Of Clinical Oncology

Today, 6:40 AM

Results show improved outcomes in overall survival in patients with HER2-positive early stage breast cancer who received ≥ 11 months of treatment with neratinib LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc.

PBYI

3 minute read

FDA
News

Puma Biotech Highlights Presentation Of Data Comparing Findings From Phase 2 CONTROL Trial With Neratinib Arm Of Phase 3 ExteNET Trial At American Society of Clinical Oncology

By Benzinga Newsdesk

Today, 6:40 AM

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, presented results at the virtual 2021 ASCO Annual Meeting comparing the diarrhea mitigation strategies investigated in the Phase II CONTROL trial with

PBYI

32 minute read

Uncategorized

Earnings Scheduled For May 6, 2021

By Benzinga Insights

Today, 6:40 AM

Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.

AAOI